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Innovation in monoclonal antibodies (mAbs) production for clinical
use continues to be driven by cell engineering strategies to increase
mAb yield and to control the complexity of advanced recycling
antibodies (rcAbs). rcAbs offer significant advantages for efficacy by
dissociating the antigens in endosomes and recycling the free antibodies
back to plasma (Ref. 1). We were able to reduce the instability in an
rcAb-producing CHO cell line whereby the mAb titer during the stage of
cell line development was decreased, and were able to improve cell
culture optimization.
In this study, we used chemically defined media (CDM) and CDM-
adapted taurine transporter-overexpressing DXB11 host cells for cell
line development for two different types of rcAb (rcAb-1, rcAb-2). These
rcAbs not only have pH-dependent antigen-binding but also a distinct
mechanism of mAb uptake into cells. As described before (Ref. 2, 3),
overexpression of taurine transporter (TAUT) is able to improve DXB11
cell performance. DXB11/TAUT host cells were further developed with
CDM, and these enabled the establishment of strains that produced
higher yields of rcAb than did DXB11 parent cells.
Yields of DXB11/TAUT/rcAb-1 strains increased up to 7.0 g/L/17 days
under 1-L bioreactor fed-batch conditions. In contrast, the mAb yields of
DXB11/rcAb-1 were up to 3.5 g/L/17 days. In addition, the mAb
properties of DXB11/TAUT/rcAb-1 were comparable to those of
DXB11/rcAb-1. These results suggest that our TAUT overexpression
strategy has a unique potential for improvement of DXB11 host cells
and is useful for the cell line development of advanced antibodies with
increased complexity. Since our cell line development of
DXB11/TAUT/rcAb-2 also shows significant promise, we plan to adopt
the DXB11/TAUT host cell as our Super CHO cell for future development
of advanced antibody drugs.
ABSTRACT
Fc engineering of rcAb-1 to enhance its binding affinity to FcRn at acidic
pH can improve pharmacokinetics by increasing the recycling efficiency.
However, it was not easy to proceed with cell line development using our
conventional platform.
Fig. 1
Mechanism of rcAb-1 action
Fig. 4
Fig. 5
Contrary to our expectations, the CHO-K1 platform was inferior to the
DXB11 platform. TAUT overexpression was not sufficient to establish
high-titer strains. But co-overexpression of TAUT with a long non-
coding RNA (Ref. 4) was able to improve CHO-K1 cell performance.
[1] The current version of the DXB11/TAUT platform process
delivers cell lines with recycling antibody yields of 7.0
g/L/17 days.
[2] The CHO-K1/TAUT platform process was not appropriate
for cell line development for recycling antibodies.
[3] Our Super CHO platform might be useful for development
of advanced drugs like sweeping antibodies.
[4] Tabuchi H. Novel strategy for a high-yielding mAb-producing CHO strain
(overexpression of non-coding RNA enhanced proliferation and improved mAb
yield) BMC Proceedings 2013;7 (Suppl 6):O3
The yields of both DXB11/TAUT/rcAb-1 and DXB11/rcAb-1 strains
increased up to 17 days under 1-L bioreactor fed-batch condition. For
DXB11/TAUT/rcAb-1 strains, especially, ideal culture profiles were
observed without process optimization.
Cell line development for rcAb-1
using DXB11/TAUT cells
TAUT overexpression was able to improve DXB11 host cell performance for the
cell line development of recycling antibody. The yields of DXB11/TAUT/rcAb-1
strains increased up to 7.0 g/L/17 days under 1-L bioreactor fed-batch
conditions. In contrast, the mAb yields of DXB11/rcAb-1 were up to 3.5 g/L/17
days.
Fig. 3
Culture profiles of 
DXB11/TAUT/rcAb-1 strains
Fig. 2
CDM-adapted DXB11 host cells were transfected with pHyg/TAUT. A
TAUT-overexpressing DXB11/TAUT cell was selected and adapted by
means of a selected seed train medium (STM) as a Super CHO cell.
Equivalence of doubling time can be seen for both host cells.
Establishment of DXB11/TAUT 
host cell
Host cells Doubling time
DXB11 27.2 ± 4.4 hrs (n=6)
(Control cell)








Cell line development for rcAb-1
using CHO-K1/TAUT cells
Mechanism of rcAb-2 action




Cell line development of DXB11/TAUT/rcAb-2 shows significant promise
at the early stage. The yield of rcAb-2 was promising for the 1st MTX
pool (1.1 g/L/14 days) and eventually increased to more than 5.0
g/L/14 days.
Fig. 7
Advanced FcgRIIb engineering for rc-Ab2 (sweeping antibody) can actively
eliminate soluble antigens from circulation.
Fig. 6
[3] Tabuchi & Sugiyama T. Cooverexpression of alanine aminotransferase 1 in
Chinese hamster ovary cells overexpressing taurine transporter further
stimulates metabolism and enhances product yield. Biotechnology and
Bioengineering 2013;110(8):2208-2215
[2] Tabuchi H. et al. Overexpression of taurine transporter in Chinese hamster
ovary cells can enhance cell viability and product yield, while promoting
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0.9 g/L/14 days
2.7 g/L/14 days [1] Igawa T. et al. Sweeping antibody as novel therapeutic antibody modality
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